Canada markets close in 4 hours 31 minutes

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
1.7500-0.0100 (-0.57%)
As of 10:34AM EDT. Market open.
Full screen
Previous Close1.7600
Open1.8000
Bid1.7400 x 0
Ask1.7500 x 0
Day's Range1.7500 - 1.8600
52 Week Range1.2100 - 2.6500
Volume17,034
Avg. Volume41,837
Market Cap68.444M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-0.3440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisabl

  • Newsfile

    NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board

    NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis" Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field o

  • Newsfile

    NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researchers to its Alzheimer's Disease Scientific Advisory Board. Drs. Martin Farlow, Reisa Sperling and Michael Weiner have agreed to join Drs. Jeffrey Cummings,